What is DXCM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 31.74B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DXCM?

P/E (TTM) is 31.86 and 52-week range is $54.11 to $92.59 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DXCM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DXCM?

The company profile lists revenue (TTM) near $4.92B, net income (TTM) near $989M, EPS (TTM) near $2.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dexcom Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 385.9M shares outstanding, ISIN US2521311074 when available from company profile and filing metadata.

Dexcom Inc

$DXCM

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$84.11

-0.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. The company enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.

Employees

11,000

Website

www.dexcom.com/

IPO

2005-04-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)